DV
Dividend Vision

NKTR — Nektar Therapeutics

Nektar Therapeutics (NKTR)

Total return is 29.8% over the past 32.3 years, 2898.5 points behind SPY at 2928.3%. Its deepest 1-year drawdown was 46.5%.

This is a single-stock equity holding in Nektar Therapeutics, a biopharmaceutical company, rather than a diversified ETF fund. As a concentrated single-stock position, it does not provide the diversification typical of ETFs and does not currently distribute dividends or have an associated expense ratio listed. This holding appeals primarily to investors seeking direct equity exposure to the biotechnology sector with a focused thesis on Nektar's pipeline and business prospects, rather than those pursuing dividend income.

NKTR key facts

Asset type
Stock
Asset class
Equity
Inception date
05/03/1994
Distribution frequency
None
Last close
$73.02
Market cap
$2,493,121,280
Average volume
828400.0
Beta
1.157
Payout ratio
0.0
Forward P/E
34.0136
EPS
$-7.93